Ensign Peak Advisors
ARQT icon

Ensign Peak Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Ensign Peak Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6M Sell
974,534
-269,853
-22% -$6.29M 0.04% 275
2026
Q1 		$29.3M Sell
1,244,387
-658,003
-35% -$16.8M 0.05% 253
2025
Q4 		$55.2M Sell
1,902,390
-90,665
-5% -$2.32M 0.1% 175
2025
Q3 		$37.6M Sell
1,993,055
-8,384
-0.4% -$132K 0.06% 235
2025
Q2 		$28.1M Buy
2,001,439
+13,050
+0.7% +$183K 0.05% 259
2025
Q1 		$31.1M Sell
1,988,389
-385,751
-16% -$5.43M 0.06% 233
2024
Q4 		$33.1M Sell
2,374,140
-42,672
-2% -$468K 0.06% 234
2024
Q3 		$22.5M Buy
2,416,812
+283,110
+13% +$2.79M 0.04% 306
2024
Q2 		$19.8M Sell
2,133,702
-846,645
-28% -$7.66M 0.04% 318
2024
Q1 		$29.5M Buy
2,980,347
+950,390
+47% +$7.09M 0.05% 255
2023
Q4 		$6.56M Buy
2,029,957
+1,203,862
+146% +$3.27M 0.01% 558
2023
Q3 		$4.39M Sell
826,095
-6,445
-0.8% -$54.8K 0.01% 607
2023
Q2 		$7.93M Buy
832,540
+346,300
+71% +$3.84M 0.02% 479
2023
Q1 		$5.35M Buy
486,240
+1,688
+0.3% +$24.4K 0.01% 547
2022
Q4 		$7.17M Sell
484,552
-4,793
-1% -$83.7K 0.02% 479
2022
Q3 		$9.35M Buy
489,345
+109,450
+29% +$2.48M 0.02% 383
2022
Q2 		$8.1M Sell
379,895
-115,555
-23% -$2.37M 0.02% 418
2022
Q1 		$9.54M Buy
495,450
+75,776
+18% +$1.28M 0.02% 435
2021
Q4 		$8.7M Buy
419,674
+29,736
+8% +$592K 0.02% 505
2021
Q3 		$9.32M Sell
389,938
-7,278
-2% -$166K 0.02% 449
2021
Q2 		$10.8M Buy
397,216
+226,013
+132% +$6.37M 0.02% 414
2021
Q1 		$4.95M Buy
171,203
+132,599
+343% +$4.14M 0.01% 624
2020
Q4 		$1.09M Buy
38,604
+16,728
+76% +$410K ﹤0.01% 1371
2020
Q3 		$641K Buy
21,876
+14,376
+192% +$384K ﹤0.01% 1462
2020
Q2 		$227K Hold
7,500
– – ﹤0.01% 1568
2020
Q1 		$224K Buy
+7,500
New +$202K ﹤0.01% 1519

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ensign Peak Advisors's ARQT Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 22% in Q2 2026, selling an estimated $6.29M and leaving 974,534 shares worth $25.6M. The position accounts for 0.04% of the portfolio, ranked #275.

Ensign Peak Advisors first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $55.2M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Ensign Peak Advisors held 974,534 shares of Arcutis Biotherapeutics worth $25.6M as of Q2 2026.
  • Ensign Peak Advisors sold 269,853 Arcutis Biotherapeutics shares in Q2 2026, an estimated $6.29M.
  • Arcutis Biotherapeutics made up 0.04% of Ensign Peak Advisors's portfolio in Q2 2026, its #275 holding.
  • Ensign Peak Advisors first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Arcutis Biotherapeutics position peaked at $55.2M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.